On June 6, 2017, KEI wrote to Dr. Thomas Price, Secretary of Health and Human Services (HHS), and Dr. Francis S. Collins, Director of the National Institutes of Health (NIH) requesting the HHS develop a policy on the licensing of federally-funded CRISPR patented inventions. A copy of our letter is available here: /node/2801.
(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) On July 10, 2017, the NIH issued a notice on “Prospective Grant of Exclusive Patent License: Composition and Methods for Delivering Inhibitory Oligonucleotides for the Treatment of… Continue Reading
These are the notes I used when providing the KEI comments at the July 25, 2017 civil society stakeholder forum at the 19th round of the RCEP negotiation.
My name is James Love. I work for Knowledge Ecology International, an NGO that focuses on the social aspects to the production, management and control of knowledge goods. I am also a member of the board of directors of the Union for Affordable Cancer Treatment.
The IP Chapter is complex, and in the time allocated, I will discuss five issues.
25 July 2017
FOR IMMEDIATE RELEASE
CONTACT: Kim Treanor, kim.treanor@keionline.org or +1 (202) 332-2670
Washington, 25 July 2017 – Knowledge Ecology International (KEI) and Médecins Sans Frontières (MSF) have sent a letter today to the Command Judge Advocate of the U.S. Army Medical Research and Materiel Command (USAMRMC), recommending two specific contractual terms for the proposed license of the US Army’s Zika vaccine technology to Sanofi Pasteur.
The attached PDF file was prepared by Dr. Diane Singhroy, for Patients for Affordable Drugs. DR. Singhroy performed a keyword search in the NIH RePorter database, (https://projectreporter.nih.gov/reporter.cfm) for all projects since 1993 containing the phrase “chimeric antigen receptor” (CAR), as… Continue Reading
(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) In 2016, the NIH signed a CRADA with NantBioScience, a company lead by Patrick Soon-Shiong, MD. to develop “Further Develop Recombinant NK Cells and Monoclonal Antibodies as… Continue Reading
On 19 July 2017, Rep. Marcy Kaptur (D-OH) introduced an amendment at the markup in the U.S. House Appropriations Committee of the FY2018 State and Foreign Operations, Labor, Health and Human Services Appropriations bill that would direct the Department of Health and Human Services to use its authority to break patent monopolies for government-funded inventions priced higher in the U.S. than seven other high-income countries.
Attached are the slides I used in today’s FDA hearing on the Hatch-Waxman Act and drug pricing. (link to PDF version of slides) Continue Reading
This afternoon USTR published a summary of the negotiating objectives for NAFTA. A press release is here. The summary report is here.
The intellectual property objectives include this welcome statement, which reflects positions taken in the past by USTR, but it not something we took for granted in the Trump Administration, and we are happy to see it.
Last week, Sanofi sent a letter to six U.S. Senators. (Copies here). We responded today. Our letter is attached here.
Some news reports about the Sanofi letter.